Traditional Chinese medicine composition for treating acute and chronic pancreatitis and application thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating acute and chronic pancreatitis. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 60-100 parts of mirabilite, 10-50 parts of raw rhubarb, 1-30 parts of prepared euphorbia kansui and 1-10 parts of borneol. The traditional Chinese medicine composition can be used for treating acute and chronic pancreatitis and can be prepared into a preparation, the traditional Chinese medicine composition can be prepared into a patch, and the patch is subjected to transdermal administration and is directly absorbed into blood through skin, so that damage to liver and kidney functions and gastric mucosa during metabolism of oral medicines can be reduced, and meanwhile, the invasive defects of injection medicines are also avoided. The traditional Chinese medicine patch prepared by the invention is clinically proved to be safe and effective, has the advantages of convenience, simplicity and easiness in operation, and is suitable for wide popularization and application.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating acute and chronic pancreatitis and its application. Background Art

[0002] Both acute pancreatitis and chronic pancreatitis are digestive medicine diseases mainly characterized by inflammatory reactions and damages of pancreatic tissue. The causes include cholelithiasis, alcoholism, hyperlipidemia, smoking, infection, etc. The pathogenesis of acute and chronic pancreatitis is related to the abnormal activation of trypsinogen, leading to local or diffuse inflammation of the pancreas.

[0003] Acute pancreatitis has a sudden onset and a rapid disease progression. If the disease development cannot be blocked in time, serious complications may occur, threatening life; while the causes of chronic pancreatitis are often difficult to completely remove, the condition progresses and worsens, and there are repeated acute attacks, severely affecting the quality of life of patients. Currently, there is no drug that can clearly treat acute and chronic pancreatitis, and the treatment mainly focuses on symptomatic treatments such as inhibiting pancreatic enzyme secretion, anti-infection, and analgesia. Therefore, exploring a safe, effective, simple-to-operate treatment method that can reduce the inflammatory reaction and damage of pancreatic tissue has important clinical significance.

[0004] As a traditional Chinese medicine therapy, traditional Chinese medicine patches are widely used in the treatment of digestive system diseases, and have the advantages of definite curative effect, simple operation, safety and reliability, etc., and are deeply favored by patients. Summary of the Invention

[0005] The purpose of the present invention is to provide a traditional Chinese medicine composition for treating acute and chronic pancreatitis.

[0006] Another purpose of the present invention is to provide an application of the traditional Chinese medicine composition in the preparation of a drug for preventing or treating acute and chronic pancreatitis.

[0007] In order to achieve the above purposes, the technical scheme adopted by the present invention is as follows:

[0008] In the first aspect of the present invention, there is provided a traditional Chinese medicine composition for treating acute and chronic pancreatitis, which is made from the following components in parts by weight: mirabilite 60 - 100 parts, raw rheum officinale 10 - 50 parts, processed kansui 1 - 30 parts, borneol 1 - 10 parts.

[0009] Preferably, the traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 70 - 100 parts, raw rheum officinale 15 - 40 parts, processed kansui 8 - 20 parts, borneol 3 - 9 parts.

[0010] Most preferably, the traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 80 parts, raw rheum officinale 30 parts, processed kansui 10 parts, borneol 5 parts.

[0011] Most preferably, the traditional Chinese medicine composition for treating acute and chronic pancreatitis is made of the following components in parts by weight: mirabilite 90 parts, raw rhubarb 40 parts, processed kansui 20 parts, borneol 8 parts.

[0012] Most preferably, the traditional Chinese medicine composition for treating acute and chronic pancreatitis is made of the following components in parts by weight: mirabilite 70 parts, raw rhubarb 15 parts, processed kansui 8 parts, borneol 3 parts.

[0013] Most preferably, the traditional Chinese medicine composition for treating acute and chronic pancreatitis is made of the following components in parts by weight: mirabilite 100 parts, raw rhubarb 25 parts, processed kansui 12 parts, borneol 9 parts.

[0014] In the second aspect of the present invention, there is provided an application of the traditional Chinese medicine composition in the preparation of a drug for preventing or treating acute and chronic pancreatitis.

[0015] In the third aspect of the present invention, there is provided a pharmaceutical preparation, which is made of the traditional Chinese medicine composition and pharmaceutically acceptable excipients.

[0016] The dosage form of the pharmaceutical preparation is an umbilical patch.

[0017] The pharmaceutically acceptable excipient is an adhesive.

[0018] In the fourth aspect of the present invention, there is provided an application of a pharmaceutical preparation in the preparation of a drug for preventing or treating acute and chronic pancreatitis.

[0019] In the traditional Chinese medicine composition of the present invention: mirabilite is the monarch drug, which is cold in nature, salty and bitter in taste, and its main effects include clearing heat and detoxifying, detumescence and pain relief, purging and relieving constipation, etc. It relieves constipation by increasing the water content in the intestine, softening the feces and promoting their excretion; at the same time, mirabilite can also reduce the inflammatory response and inhibit the growth of bacteria. Raw rhubarb is the minister drug, which is cold in nature and bitter in taste, and has the effects of detumescence and removing carbuncles, detoxifying, purging heat and relieving constipation, etc. It can not only stimulate the intestinal mucosa, accelerate intestinal peristalsis and secretion, and promote the excretory function, but also inhibit the growth and reproduction of bacteria, viruses and fungi, and has a wide range of antibacterial effects. Processed kansui is the minister drug, which is cold in nature and bitter in taste, and has the effect of drastic purgation and diuresis, promoting urine excretion and relieving the symptom of body edema. Borneol is the minister drug, which is pungent, bitter and slightly cold in nature, and has the effects of clearing heat and detoxifying, detumescence and pain relief, relieving sore throat and opening the voice, etc. It can not only play its role of clearing heat and detoxifying by reducing body temperature and relieving inflammation, but also disperse stasis and detumescence, and has an improvement effect on local pain, swelling and other symptoms. The whole formula plays the roles of clearing heat and detoxifying, promoting diuresis and purging the bowels, detumescence and pain relief.

[0020] The nature, flavor, meridian tropism and functions and indications of the traditional Chinese medicine raw materials of the present invention are as follows:

[0021] Mirabilite: Cold in nature, salty and bitter in taste. It acts on the stomach and large intestine meridians. It has the effects of clearing heat and detoxifying, reducing swelling and alleviating pain, and inducing purgation for relieving constipation. It is mainly used to treat excess heat accumulation and stagnation, abdominal fullness and distending pain, dry and hard stools, appendicitis with swelling and pain, and externally for mammary abscess and swelling and pain of hemorrhoids.

[0022] Raw rhubarb: Cold in nature, bitter in taste. It acts on the stomach, large intestine, liver and spleen meridians. It has the effects of reducing swelling and dispelling carbuncles, detoxifying, and purging heat for relieving constipation. It is mainly used to treat pyogenic infections, stagnant constipation, hematemesis and epistaxis due to blood heat, damp-heat dysentery, jaundice, stranguria, and various stasis syndromes.

[0023] Prepared kansui: Cold in nature, bitter in taste. It acts on the lung, spleen and kidney meridians. It is mainly used to treat edema, ascites, retention of fluid with chest binding, epilepsy, wheezing and coughing, and obstruction of defecation and urination.

[0024] Borneol: Slightly cold in nature, pungent and bitter in taste. It acts on the heart, spleen and lung meridians. It has the effects of clearing heat and detoxifying, reducing swelling and alleviating pain, and promoting the voice. It is mainly used to treat coma due to febrile disease, convulsion, syncope due to phlegm in stroke, sudden syncope due to qi stagnation, syncope due to pestilence, chest impediment with heart pain, red eyes, oral ulcers, sore throat, and purulent ear discharge.

[0025] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0026] The traditional Chinese medicine composition of the present invention can treat acute and chronic pancreatitis. The traditional Chinese medicine composition can be made into a preparation. The present invention makes the traditional Chinese medicine composition into a patch. The patch is for transdermal administration and directly absorbs through the skin into the blood, which can reduce the damage to the liver and kidney functions and gastric mucosa during the metabolism of oral drugs. At the same time, it also avoids the invasive disadvantages of injection. The traditional Chinese medicine patch prepared by the present invention has been clinically proven to be safe and effective, and has the advantages of convenience, simplicity and easy operation, and is suitable for wide promotion and use. Specific embodiments

[0027] In order to more clearly illustrate the present invention, the present invention will be further described below in conjunction with preferred embodiments. Those skilled in the art should understand that the specific content described below is illustrative rather than restrictive, and should not be used to limit the protection scope of the present invention.

[0028] For the experimental methods without specific conditions noted in the following examples, they are usually in accordance with conventional conditions or in accordance with the conditions recommended by the manufacturer. The medicinal materials used in the embodiments of the present invention can be obtained from Chinese medicinal material sales companies unless otherwise noted. The obtained medicinal materials are Chinese medicinal material decoction pieces unless otherwise noted. The decoction pieces can be obtained from the sales company or processed after obtaining.

[0029] Example 1

[0030] A traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 80 g, raw rhubarb 30 g, prepared kansui 10 g, borneol 5 g.

[0031] The preparation method of the umbilical therapy patch comprises the following steps:

[0032] Mix and pulverize each raw material drug, and pass through an 80-mesh sieve. Weigh 2400 g of each pulverized component raw material drug according to the above ratio, add 1000 g of maltose and stir evenly to form a thick paste, and spread it into a plaster with a crescent-shaped template to obtain 150 umbilical therapy patches.

[0033] When in use, apply it to the surface mapping part of the pancreas on the upper abdomen of the patient, one patch per day, maintain for more than 6 hours, and one week is one course of treatment.

[0034] Example 2

[0035] A traditional Chinese medicine composition for treating acute and chronic pancreatitis is made of the following components in parts by weight: mirabilite 90 g, raw rhubarb 40 g, prepared kansui 20 g, borneol 8 g.

[0036] The preparation method of the umbilical therapy patch comprises the following steps:

[0037] Mix and pulverize each raw material drug, and pass through an 80-mesh sieve. Weigh 2400 g of each pulverized component raw material drug according to the above ratio, add 1000 g of maltose and stir evenly to form a thick paste, and spread it into a plaster with a crescent-shaped template to obtain 150 umbilical therapy patches.

[0038] When in use, apply it to the surface mapping part of the pancreas on the upper abdomen of the patient, one patch per day, maintain for more than 6 hours, and one week is one course of treatment.

[0039] Example 3

[0040] A traditional Chinese medicine composition for treating acute and chronic pancreatitis is made of the following components in parts by weight: mirabilite 70 g, raw rhubarb 15 g, prepared kansui 8 g, borneol 3 g.

[0041] The preparation method of the umbilical therapy patch comprises the following steps:

[0042] Mix and pulverize each raw material drug, and pass through an 80-mesh sieve. Weigh 2400 g of each pulverized component raw material drug according to the above ratio, add 1000 g of maltose and stir evenly to form a thick paste, and spread it into a plaster with a crescent-shaped template to obtain 150 umbilical therapy patches.

[0043] When in use, apply it to the surface mapping part of the pancreas on the upper abdomen of the patient, one patch per day, maintain for more than 6 hours, and one week is one course of treatment.

[0044] Example 4

[0045] A traditional Chinese medicine composition for treating acute and chronic pancreatitis is made of the following components in parts by weight: mirabilite 100 g, raw rhubarb 25 g, prepared kansui 12 g, borneol 9 g.

[0046] The preparation method of the umbilical therapy patch comprises the following steps:

[0047] Mix the raw medicinal materials evenly and crush them, then pass through an 80-mesh sieve. Weigh 2400 g of each component of the crushed raw materials according to the above ratio, add 1000 g of maltose and stir evenly to make a thick paste, and spread it into plasters with a crescent-shaped template to obtain 150 umbilical therapy plasters.

[0048] When in use, apply it to the surface mapping area of the pancreas on the upper abdomen of the patient, 1 plaster per day, for more than 6 hours, and 1 week is a course of treatment.

[0049] Example 5

[0050] Clinical experiment

[0051] 1. Clinical data

[0052] 1.1 General information

[0053] Sixty-four patients diagnosed with acute pancreatitis (including pancreatitis after ERCP) and 76 patients with chronic pancreatitis admitted to the digestive ward and outpatient clinic of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January to December 2024 were selected. The patients with acute pancreatitis and chronic pancreatitis were divided into a control group and an observation group by using the digital random method. There were 32 cases in each of the control group and the observation group of acute pancreatitis. In the observation group, there were 22 males and 10 females, with an age of 47.88±15.96 years; in the control group, there were 20 males and 12 females, with an age of 52.78±13.23 years. There were 38 cases in each of the observation group and the control group of chronic pancreatitis. In the observation group, there were 24 males and 14 females, with an age of 43.2±7.5 years; in the control group, there were 26 males and 12 females, with an age of 44.1±7.9 years. There were no statistically significant differences in the general information such as the gender and age of the patients (P>0.05), and they were comparable.

[0054] 1.2 Diagnostic criteria

[0055] Diagnostic criteria for acute pancreatitis: Clinical manifestations: Patients often present with acute upper abdominal pain, accompanied by symptoms such as nausea, vomiting, and abdominal distension. The abdominal pain can radiate to the waist and back and cannot be relieved by antispasmodic and analgesic drugs. Laboratory tests: The levels of serum amylase and / or lipase are at least three times higher than the normal upper limit. Imaging examination: Abdominal ultrasound or CT examination shows obvious inflammation, edema, or exudation of the pancreas.

[0056] Diagnostic criteria for chronic pancreatitis: Clinical manifestations: Patients have a history of recurrent acute pancreatitis and present with symptoms such as persistent weight loss and upper abdominal pain. Imaging examination: CT or MRI examination shows characteristic changes of chronic pancreatitis such as pancreatic calcification, atrophy, or pancreatic duct stones.

[0057] 1.3 Inclusion criteria: Meeting the above diagnostic criteria; Aged between 18 and 65 years old; Patients who voluntarily participate in this study and sign the informed consent form.

[0058] 1.4 Exclusion criteria:

[0059] (1) Suffering from other serious diseases, such as malignant tumors, severe cardiovascular diseases, etc. (2) Having a history of allergy to the study drugs or treatment methods. (3) Pregnant or lactating women. (4) Patients with mental diseases.

[0060] 1.5 Exclusion criteria:

[0061] (1) Those who entered by mistake and did not meet the inclusion criteria; (2) Those with incomplete research data that affect the determination of curative effect; (3) Those who did not take medicine as required by the research protocol; (4) Those who had serious adverse events during the treatment process.

[0062] 2. Research methods:

[0063] 2.1 Treatment methods:

[0064] The control group was given conventional treatment according to the diagnosis and treatment consensus. The patients in the observation group were given the umbilical therapy patch prepared in Example 1 of the present invention on the basis of conventional treatment, 1 patch per day (at 8 o'clock in the morning), maintained for more than 6 hours, and treated for 1 week.

[0065] 2.2 Efficacy observation indicators

[0066] 2.2.1 Acute pancreatitis:

[0067] (1) The APACHE II scoring system was calculated before treatment and 1 week after treatment respectively.

[0068] (2) Serum biochemical and inflammatory indicators, including C-reactive protein CRP, blood amylase, and serum lipase, were detected before treatment and 1 week after treatment respectively.

[0069] 2.2.2 Chronic pancreatitis:

[0070] (1) The time to relieve abdominal pain (days), the length of hospital stay (days), and the hospitalization cost.

[0071] (2) Serum inflammatory indicator IL-6 was detected before treatment and 1 week after treatment respectively.

[0072] 2.3 Safety observation

[0073] During the treatment period, the occurrence of adverse events in patients was observed and recorded, mainly including skin allergy, local pain, etc. of patients.

[0074] 2.4 Statistical methods

[0075] SPSS 23.0 software was used for statistical analysis of the data. Measurement data were expressed as , and the paired-sample t-test was selected as the statistical method. The result with P < 0.05 was considered statistically significant.

[0076] 3. Results

[0077] 3.1 Acute pancreatitis

[0078] 3.1.1 Comparison of APACHE II scores before and after treatment (points, ) The results are shown in Table 1 as follows:

[0079] Table 1

[0080]

[0081] Note: Compared with before treatment, △ P < 0.05; compared with the control group, * P < 0.05.

[0082] As can be seen from Table 1, compared with before treatment, the APACHE II scores of both the observation group and the control group decreased after treatment, and the difference was statistically significant (P < 0.05), indicating that the treatments in both groups were effective. And the APACHE II score of the observation group after treatment was lower than that of the control group, with a statistically significant difference (P < 0.05), suggesting that the curative effect of the observation group was better than that of the control group.

[0083] 3.1.2 Comparison of biochemical and inflammatory indexes before and after treatment ( ) The results are shown in Table 2 as follows:

[0084] Table 2

[0085]

[0086] Note: Compared with before treatment, △ P < 0.05; compared with the control group, * P < 0.05.

[0087] As can be seen from Table 2, compared with before treatment, CRP, amylase, and lipase in both the observation group and the control group decreased after treatment, and the difference was statistically significant (P < 0.05), indicating that the treatments in both groups were effective. And CRP, amylase, and lipase in the observation group after treatment were lower than those in the control group, with a statistically significant difference (P < 0.05), suggesting that the curative effect of the observation group was better than that of the control group.

[0088] 3.2 Chronic pancreatitis

[0089] 3.2.1 Duration of abdominal pain relief, length of hospital stay, and hospitalization expenses ( ) The results are shown in Table 3 as follows:

[0090] Table 3

[0091]

[0092] Note: Compared with the control group, * P < 0.05.

[0093] As can be seen from Table 3, compared with the control group, the abdominal pain relief time in the observation group was faster, the length of hospital stay was shorter, and the hospitalization cost was also lower. The differences were all statistically significant (P < 0.05), indicating that the curative effect of the observation group was better than that of the control group.

[0094] 3.2.2 Comparison of inflammatory index IL-6 before and after treatment (pg / mL, ) The results are shown in Table 4:

[0095] Table 4

[0096]

[0097] Note: Compared with the control group, * P < 0.05.

[0098] As can be seen from Table 4, compared with before treatment, IL-6 in the observation group decreased, and the difference was statistically significant (P < 0.05). Although IL-6 in the control group decreased, the difference was not statistically significant (P > 0.05), indicating that the curative effect of the observation group was better than that of the control group.

[0099] 4. Conclusion

[0100] The umbilical therapy patch prepared by the present invention can effectively reduce the pancreatic inflammatory reaction, accelerate the recovery of the disease, shorten the length of hospital stay, reduce the treatment cost, and relieve the economic burden of patients in the treatment of acute and chronic pancreatitis.

[0101] Example 6

[0102] Patient Zhang, male, 47 years old, has a history of chronic pancreatitis for 13 years. He was admitted to the hospital on November 5, 2024 for "chronic pancreatitis, pancreatic duct stones, hypertension grade 3, and type 2 diabetes" due to "repeated upper abdominal pain for more than one month". MRCP was performed on admission (November 5, 2024) and found that the pancreatic duct in the pancreatic neck, body and tail was uneven in thickness and signal, and pancreatic duct stones with chronic inflammatory disease were considered. The pancreas was swollen and the surrounding fat gap was blurred, considering the possibility of combined acute inflammation. The common bile duct was slightly dilated, with blood amylase 226U / L; IL-6 278pg / mL. On admission to the hospital, anti-infection, pancreatic enzyme inhibition, and nutritional support were given on the basis of conventional treatment, and the umbilical therapy patch prepared in Example 1 of the present invention was applied externally, 1 patch per day (8 o'clock in the morning), and maintained for more than 6 hours. On November 12, 2024, blood amylase was rechecked to 106U / L; IL-6124pg / mL. The abdominal pain symptoms were significantly relieved and he was discharged from the hospital on November 14, 2024. He was hospitalized for 9 days and the hospitalization cost was 18,628 yuan.

[0103] Example 7

[0104] Patient Xu, female, 41 years old, was admitted to the hospital for "acute pancreatitis" on November 3, 2024 due to "upper abdominal discomfort accompanied by nausea and vomiting for 2 days". On November 2, 2024, blood amylase was 472U / L; blood lipase was 630U / L; CRP was 125.86mg / L. On November 3, 2024, upper abdominal CT showed multiple blurred shadows around the pancreas, and acute pancreatitis was considered. The APACHE II score on admission was 16 points. On admission, the umbilical therapy patch prepared in Example 1 of the present invention was applied externally on the basis of basic treatments such as fasting, anti-infection, and inhibition of pancreatic enzymes, 1 patch per day (8 o'clock in the morning), and maintained for more than 6 hours. On November 8, 2024, blood amylase was rechecked to be 107U / L; blood lipase was 77U / L; CRP was 12.11mg / L, and the APACHE II score was 1 point. After treatment, the symptoms were relieved and he was discharged from the hospital on November 10, 2024.

[0105] Example 8

[0106] Patient Wang, female, 40 years old, was admitted to the hospital for "acute pancreatitis" on September 26, 2024 due to "swelling and pain in the middle and upper abdomen for 5 days". On September 26, 2024, blood amylase was 559U / L; blood lipase was 7230U / L; CRP was 143.72mg / L. MRCP indicated acute edematous pancreatitis. APACHE II score of 18 points on admission. On admission, the umbilical therapy patch prepared in Example 1 of the present invention was applied externally on the basis of basic treatments such as fasting, anti-infection, and inhibition of pancreatic enzymes, 1 patch per day (8 o'clock in the morning), and maintained for more than 6 hours. On October 5, 2024, blood amylase was rechecked to 68U / L; blood lipase was 27U / L; CRP was 6.52mg / L, and APACHE II score was 1 point. After treatment, the symptoms were relieved and he was discharged on October 6, 2024.

[0107] The above are only the preferred embodiments of the present invention, and do not impose any form of limitation on the present invention. Although the present invention has been disclosed above with the preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art of this patent, without departing from the scope of the technical solution of the present invention, can make some changes or modifications using the technical content prompted above to equivalent embodiments of equivalent changes. However, as long as it does not depart from the content of the technical solution of the present invention, any simple modification, equivalent change and modification made to the above embodiments based on the technical essence of the present invention still fall within the scope of the present invention's solution.

Claims

1. A traditional Chinese medicine composition for treating acute and chronic pancreatitis, characterized in that, It is made from the following components in parts by weight: mirabilite 60 - 100 parts, raw rhubarb 10 - 50 parts, processed kansui 1 - 30 parts, borneol 1 - 10 parts.

2. The traditional Chinese medicine composition for treating acute and chronic pancreatitis according to claim 1, wherein, The traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 70 - 100 parts, raw rhubarb 15 - 40 parts, processed kansui 8 - 20 parts, borneol 3 - 9 parts.

3. The traditional Chinese medicine composition for treating acute and chronic pancreatitis according to claim 1, wherein The traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 80 parts, raw rhubarb 30 parts, processed kansui 10 parts, borneol 5 parts.

4. The traditional Chinese medicine composition for treating acute and chronic pancreatitis according to claim 1, wherein, The traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 90 parts, raw rhubarb 40 parts, processed kansui 20 parts, borneol 8 parts.

5. The traditional Chinese medicine composition for treating acute and chronic pancreatitis according to claim 1, wherein, The traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 70 parts, raw rhubarb 15 parts, processed kansui 8 parts, borneol 3 parts.

6. The traditional Chinese medicine composition for treating acute and chronic pancreatitis according to claim 1, wherein The traditional Chinese medicine composition for treating acute and chronic pancreatitis is made from the following components in parts by weight: mirabilite 100 parts, raw rhubarb 25 parts, processed kansui 12 parts, borneol 9 parts.

7. Use of the traditional Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a drug for preventing or treating acute and chronic pancreatitis.

8. A pharmaceutical preparation, characterized in that, It is made from the traditional Chinese medicine composition according to any one of claims 1 to 6 and pharmaceutically acceptable excipients.

9. The pharmaceutical preparation according to claim 8, wherein The dosage form of the pharmaceutical preparation is an umbilical patch.

10. Use of the pharmaceutical preparation according to claim 8 or 9 in the preparation of a drug for preventing or treating acute and chronic pancreatitis.

Images